306 related articles for article (PubMed ID: 33007046)
1. 4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp.
Veggi D; Bianchi F; Santini L; Lo Surdo P; Chesterman CC; Pansegrau W; Bechi N; Huang Y; Masignani V; Pizza M; Rappuoli R; Bottomley MJ; Cozzi R; Maione D
PLoS Pathog; 2020 Oct; 16(10):e1008882. PubMed ID: 33007046
[TBL] [Abstract][Full Text] [Related]
2. A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine.
Beernink PT; Vianzon V; Lewis LA; Moe GR; Granoff DM
mBio; 2019 Jun; 10(3):. PubMed ID: 31213564
[TBL] [Abstract][Full Text] [Related]
3. Cocrystal structure of meningococcal factor H binding protein variant 3 reveals a new crossprotective epitope recognized by human mAb 1E6.
Bianchi F; Veggi D; Santini L; Buricchi F; Bartolini E; Lo Surdo P; Martinelli M; Finco O; Masignani V; Bottomley MJ; Maione D; Cozzi R
FASEB J; 2019 Nov; 33(11):12099-12111. PubMed ID: 31442074
[TBL] [Abstract][Full Text] [Related]
4. Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding.
Costa I; Pajon R; Granoff DM
mBio; 2014 Aug; 5(5):e01625-14. PubMed ID: 25161192
[TBL] [Abstract][Full Text] [Related]
5. Meningococcal Factor H Binding Protein Vaccine Antigens with Increased Thermal Stability and Decreased Binding of Human Factor H.
Rossi R; Konar M; Beernink PT
Infect Immun; 2016 Jun; 84(6):1735-1742. PubMed ID: 27021245
[TBL] [Abstract][Full Text] [Related]
6. Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine.
Granoff DM; Costa I; Konar M; Giuntini S; Van Rompay KK; Beernink PT
J Infect Dis; 2015 Sep; 212(5):784-92. PubMed ID: 25676468
[TBL] [Abstract][Full Text] [Related]
7. Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses?
Granoff DM; Ram S; Beernink PT
Clin Vaccine Immunol; 2013 Aug; 20(8):1099-107. PubMed ID: 23740919
[TBL] [Abstract][Full Text] [Related]
8. Effect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccine.
Giuntini S; Beernink PT; Granoff DM
Vaccine; 2015 Dec; 33(51):7168-7175. PubMed ID: 26562320
[TBL] [Abstract][Full Text] [Related]
9. Functional Analysis of the Human Antibody Response to Meningococcal Factor H Binding Protein.
Beernink PT; Giuntini S; Costa I; Lucas AH; Granoff DM
mBio; 2015 Jun; 6(3):e00842. PubMed ID: 26106082
[TBL] [Abstract][Full Text] [Related]
10. Anti-Factor H Antibody Reactivity in Young Adults Vaccinated with a Meningococcal Serogroup B Vaccine Containing Factor H Binding Protein.
Sharkey K; Beernink PT; Langley JM; Gantt S; Quach C; Dold C; Liu Q; Galvan M; Granoff DM
mSphere; 2019 Jul; 4(4):. PubMed ID: 31270173
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activity.
Giuntini S; Beernink PT; Reason DC; Granoff DM
PLoS One; 2012; 7(3):e34272. PubMed ID: 22461909
[TBL] [Abstract][Full Text] [Related]
12. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.
Pajon R; Fergus AM; Koeberling O; Caugant DA; Granoff DM
PLoS Negl Trop Dis; 2011 Sep; 5(9):e1302. PubMed ID: 21909444
[TBL] [Abstract][Full Text] [Related]
13. Neisseria meningitidis Urethritis Outbreak Isolates Express a Novel Factor H Binding Protein Variant That Is a Potential Target of Group B-Directed Meningococcal (MenB) Vaccines.
Tzeng YL; Giuntini S; Berman Z; Sannigrahi S; Granoff DM; Stephens DS
Infect Immun; 2020 Nov; 88(12):. PubMed ID: 32958529
[TBL] [Abstract][Full Text] [Related]
14. Two human antibodies to a meningococcal serogroup B vaccine antigen enhance binding of complement Factor H by stabilizing the Factor H binding site.
Sands NA; Beernink PT
PLoS Pathog; 2021 Jun; 17(6):e1009655. PubMed ID: 34125873
[TBL] [Abstract][Full Text] [Related]
15. Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules.
Johnson S; Tan L; van der Veen S; Caesar J; Goicoechea De Jorge E; Harding RJ; Bai X; Exley RM; Ward PN; Ruivo N; Trivedi K; Cumber E; Jones R; Newham L; Staunton D; Ufret-Vincenty R; Borrow R; Pickering MC; Lea SM; Tang CM
PLoS Pathog; 2012; 8(10):e1002981. PubMed ID: 23133374
[TBL] [Abstract][Full Text] [Related]
16. Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding.
Giuntini S; Reason DC; Granoff DM
Infect Immun; 2011 Sep; 79(9):3751-9. PubMed ID: 21708990
[TBL] [Abstract][Full Text] [Related]
17. Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.
Giuntini S; Pajon R; Ram S; Granoff DM
Infect Immun; 2015 Apr; 83(4):1536-45. PubMed ID: 25644002
[TBL] [Abstract][Full Text] [Related]
18. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination.
Beernink PT; Shaughnessy J; Braga EM; Liu Q; Rice PA; Ram S; Granoff DM
J Immunol; 2011 Mar; 186(6):3606-14. PubMed ID: 21325619
[TBL] [Abstract][Full Text] [Related]
19. Two cross-reactive monoclonal antibodies recognize overlapping epitopes on Neisseria meningitidis factor H binding protein but have different functional properties.
Faleri A; Santini L; Brier S; Pansegrau W; Lo Surdo P; Scarselli M; Buricchi F; Volpini G; Genovese A; van der Veen S; Lea S; Tang CM; Savino S; Pizza M; Finco O; Norais N; Masignani V
FASEB J; 2014 Apr; 28(4):1644-53. PubMed ID: 24371123
[TBL] [Abstract][Full Text] [Related]
20. A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine.
Pajon R; Lujan E; Granoff DM
Vaccine; 2016 Jan; 34(5):643-649. PubMed ID: 26709637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
